Results from the Phase 3 trial of US biotech Moderna’s mRNA-1273 Covid-19 vaccine candidate unveiled on Nov. 15 showed it to be 94.5% effective against the novel...

Phase 3 clinical trials with the mRNA vaccine candidate BNT162b2 being developed by US pharma giant Pfizer and German biotech partner BioNTech have shown it to be more...

US vaccine manufacturer Moderna has tapped Takeda as marketing partner for its Covid-19 vaccine candidate mRNA-1273f in Japan. Financial terms of the deal were not...

On November 1, 2020, Sean Diver took the reins as President of the Drug, Chemical & Associated Technologies Association (DCAT).

French pharma Sanofi is boosting once again its immunology portfolio with an agreement to buy Dutch biotech Kiadis for €308 million.

French and British drugmakers Sanofi and GlaxoSmithKline (GSK) have signed on with Gavi, the global vaccine alliance, to make 200 million doses of their experimental...

Germany’s Merck KGaA has agreed to collaborate with Mammoth Biosciences on development, scale-up and commercial production of the US biotech’s CRISPR-based SARS CoV-2...

In its biggest pharma acquisition since the 2006 takeover of Berlin-based women’s specialist Schering, Bayer plans to plunk down up to $4 billion for US biotech firm...

Swiss pharma Roche has agreed to collaborate with US biotech Dyno Therapeutics to develop adeno-associated virus (AAV) vectors for gene therapies for central nervous...

So far, the pharmaceutical industry — including CMOs/CDMOs and CROs — has responded well to the outbreak of the Covid-19 pandemic. However, the coronavirus crisis has...